Drug Development Engineering Immune Response 
Codon
SEPTEMBER 29, 2024
It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. Unlike what many predicted, the rise of computation as a dominant force in drug development did not kill “Big Pharma.” A flurry of new, promising therapeutic targets arose.
Broad Institute
OCTOBER 11, 2023
The drugs work by blocking a protein, PD-1 — which helps keep immune responses in check — and stimulating the immune system to attack tumors. We wanted to see whether there were as yet undiscovered drug targets that would lead to amazing cancer immunotherapies,” Manguso said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
OCTOBER 2, 2023
These peptides are a vital part of the immune system’s display-recognition mechanism that enables T cells to distinguish between self and non-self-antigens, recognizing intruders to initiate immune responses.
Drug Target Review
JANUARY 15, 2024
To be therapeutically useful, antigenic peptides must be presented in a way that allows immune responses to destroy cancer cells without causing unacceptable damage to healthy tissue. With convergent technology, it is possible to engineer monoclonal antibodies that mimic the specificity of TCRs for tumour‑specific pHLA targets.
Codon
NOVEMBER 3, 2024
As an undergraduate biology student, I spent some time in a TB lab working on antibiotic resistance — a growing concern for drug developers. Testing the engineered cells against four common drugs, I found that the M. tuberculosis. A Peace Corps Volunteer administers the BCG vaccine to a six-year-old Korean boy.
NIH Director's Blog: Drug Development
FEBRUARY 1, 2022
The NIH continues to support the development of some very innovative therapies to control SARS-CoV-2, the coronavirus that causes COVID-19. They found in mouse models of severe COVID-19 that intravenous infusion of an engineered ACE2 decoy prevented lung damage and death. How’s that?
Codon
FEBRUARY 13, 2024
Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. Locus has products in development targeting four common sources of bacterial infections: E.
Expert insights. Personalized for you.
141 
Let's personalize your content